Cystoid Macular Edema – Pipeline Review, H1 2012 by GlobalMarketsDirect

VIEWS: 4 PAGES: 37

More Info
									      Cystoid Macular Edema – Pipeline Review, H1 2012


                                                                                          Reference Code: GMDHC1860IDB
                                                                                             Publication Date: March 2012




Cystoid Macular Edema – Pipeline Review, H1 2012                                            GMDHC1860IDB / Pub March 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                           Page(1)
Cystoid Macular Edema – Pipeline Review, H1 2012




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 4
    List of Figures ................................................................................................................................................................................ 4
Introduction......................................................................................................................................................................................... 5
    Global Markets Direct Report Coverage ........................................................................................................................................ 5
Cystoid Macular Edema Overview ..................................................................................................................................................... 6
Therapeutics Development................................................................................................................................................................. 7
    An Overview of Pipeline Products for Cystoid Macular Edema ..................................................................................................... 7
Cystoid Macular Edema Therapeutics under Development by Companies ........................................................................................ 9
Cystoid Macular Edema Therapeutics under Investigation by Universities/Institutes ....................................................................... 10
Late Stage Products ......................................................................................................................................................................... 11
    Comparative Analysis .................................................................................................................................................................. 11
Mid Clinical Stage Products.............................................................................................................................................................. 12
    Comparative Analysis .................................................................................................................................................................. 12
Early Clinical Stage Products ........................................................................................................................................................... 13
    Comparative Analysis .................................................................................................................................................................. 13
Cystoid Macular Edema Therapeutics – Products under Development by Companies.................................................................... 14
Cystoid Macular Edema Therapeutics – Products under Investigation by Universities/Institutes ..................................................... 15
Companies Involved in Cystoid Macular Edema Therapeutics Development................................................................................... 16
    Icon Bioscience, Inc..................................................................................................................................................................... 16
Cystoid Macular Edema – Therapeutics Assessment ...................................................................................................................... 17
    Assessment by Monotherapy Products ....................................................................................................................................... 17
    Assessment by Combination Products ........................................................................................................................................ 18
    Assessment by Route of Administration ...................................................................................................................................... 19
    Assessment by Molecule Type .................................................................................................................................................... 21
Drug Profiles..................................................................................................................................................................................... 23
    IBI-20089 - Drug Profile ............................................................................................................................................................... 23
         Product Description................................................................................................................................................................. 23
         Mechanism of Action ............................................................................................................................................................... 23
         R&D Progress ......................................................................................................................................................................... 23
    Avastin - Drug Profile................................................................................................................................................................... 25
         Product Description................................................................................................................................................................. 25
         Mechanism of Action ............................................................................................................................................................... 25
         R&D Progress ......................................................................................................................................................................... 25
    Raptiva - Drug Profile .................................................................................................................................................................. 27
         Product Description................................................................................................................................................................. 27
         Mechanism of Action ............................................................................................................................................................... 27
         R&D Progress ......................................................................................................................................................................... 27
    interferon alpha 2a + prednisone - Drug Profile ........................................................................................................................... 28
         Product Description................................................................................................................................................................. 28
         Mechanism of Action ............................................................................................................................................................... 28
         R&D Progress ...........................................................................................................................................
								
To top